Related Experiment Video
Updated: May 31, 2025
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
SSTR2-Targeted Theranostics in Hepatocellular Carcinoma
Majid Momeny1, Solmaz AghaAmiri1, Servando Hernandez Vargas1
1The Brown Foundation Institute of Molecular Medicine, McGovern Medical School, The University of Texas Health Science Center, Houston, TX 77054, USA.
Background:
While the clinical use of radiolabeled somatostatin analogs is well established in neuroendocrine tumors, there is growing interest in expanding their application to other somatostatin receptor 2 (SSTR2)-expressing cancers. This study investigates the potential utility of SSTR2-targeted theranostics in hepatocellular carcinoma (HCC).
Methods:
SSTR2 expression in HCC cell lines and clinical samples was evaluated using qRT-PCR, Western blot analysis, and a public dataset. 67Ga-DOTATATE uptake was measured, 177Lu-DOTATATE cytotoxicity was assessed, and 68Ga-DOTATATE tumor targeting was evaluated in HCC animal models and a patient via PET/CT imaging.
Results:
SSTR2 expression was confirmed in HCC cell lines and clinical samples. Radioligand uptake studies demonstrated SSTR2-mediated 67Ga-DOTATATE uptake. 177Lu-DOTATATE treatment reduced cell proliferation and enhanced the anti-tumor efficacy of the multikinase inhibitor sorafenib. 68Ga-DOTATATE PET/CT scans successfully identified tumors in HCC animal models and spinal metastases in a patient with HCC.
Conclusion:
These findings provide evidence that SSTR2-based theranostics could have significant implications for the detection and treatment of HCC.
Insights
Somatostatin receptor 2 (SSTR2)-targeted theranostics show promise for hepatocellular carcinoma (HCC). This study confirms SSTR2 expression in HCC and demonstrates the diagnostic and therapeutic potential of radiolabeled analogs for detecting and treating this cancer.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiopharmaceutical Therapy
Background:
- Radiolabeled somatostatin analogs are established for neuroendocrine tumors.
- There is increasing interest in SSTR2-targeted agents for other cancers.
- This study explores SSTR2 theranostics in hepatocellular carcinoma (HCC).
Purpose of the Study:
- To evaluate the expression of somatostatin receptor 2 (SSTR2) in hepatocellular carcinoma (HCC).
- To assess the diagnostic and therapeutic potential of SSTR2-targeted radiopharmaceuticals in HCC.
- To investigate the combination of SSTR2-targeted therapy with sorafenib in HCC.
Main Methods:
- SSTR2 expression was analyzed in HCC cell lines and clinical samples using qRT-PCR, Western blot, and public data.
- Radioligand uptake (67Ga-DOTATATE), cytotoxicity (177Lu-DOTATATE), and tumor targeting (68Ga-DOTATATE PET/CT) were evaluated.
- Animal models and a patient with HCC were used for in vivo imaging and therapeutic assessment.
Main Results:
- SSTR2 expression was confirmed in HCC cell lines and patient samples.
- 67Ga-DOTATATE showed SSTR2-mediated uptake in HCC.
- 177Lu-DOTATATE reduced HCC cell proliferation and enhanced sorafenib's anti-tumor effect.
- 68Ga-DOTATATE PET/CT successfully identified HCC tumors and metastases.
Conclusions:
- SSTR2-based theranostics demonstrate significant potential for HCC detection and treatment.
- These findings support the clinical utility of SSTR2-targeted agents in managing hepatocellular carcinoma.
More Related Videos
09:11Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
